abstract

Polycystic Ovary Syndrome (PCOS) is a multifaceted endocrine disorder characterized by hyperandrogenism, insulin resistance, and reproductive dysfunction. The management of PCOS often involves pharmacological interventions aimed at alleviating symptoms and improving metabolic and reproductive outcomes. This randomized controlled trial (RCT) compares the efficacy of antiandrogen therapy with insulin-sensitizing agents in managing PCOS symptoms. A total of 200 women diagnosed with PCOS based on the Rotterdam criteria were randomly assigned to receive either spironolactone (an antiandrogen), metformin (an insulin sensitizer), or a combination of both over a 12-month period. The primary outcomes measured included changes in hirsutism (Ferriman-Gallwey score), insulin resistance (HOMA-IR), and menstrual regularity. Secondary outcomes encompassed quality of life assessments and adverse effects. The study found that while both therapies significantly improved PCOS symptoms, the combination therapy yielded the most substantial benefits in reducing hirsutism and insulin resistance. These findings suggest that a combined therapeutic approach may offer superior outcomes in the management of PCOS.